🕵️ Tscan Therapeutics, Inc. ($TCRX)
SEC insider & ownership activity, last 12 months · CIK 1783328 · every row links its SEC filing
Over the last 12 months insiders bought $146K with no open-market selling against it. LYNX1 Capital Management LP bought $146K in discretionary trades (Dec). No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
1 buyer, $146K (3 lots) · 0 sellers, $0 (0 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| LYNX1 Capital Management LP | 3 | $146K | 0 | – | Dec 23, 2025 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| LYNX1 Capital Management LP | 15.0% | 13G | Aug 14, 2025 | filing ↗ | |
| Weston Nichols | 15.0% | 13G | Aug 14, 2025 | filing ↗ | |
| BVF Partners L P/IL | 10.0% | 13G | May 15, 2026 | filing ↗ | |
| BVF INC/IL | 10.0% | 13G | May 15, 2026 | filing ↗ | |
| Mark N. Lampert | 10.0% | 13G | May 15, 2026 | filing ↗ | |
| BVF GP Holdings LLC | 8.7% | 13G | May 15, 2026 | filing ↗ | |
| K2 Healthventures Equity Trust LLC | 6.9% | 13G | Feb 14, 2025 | filing ↗ | |
| Parag Shah | 6.9% | 13G | Feb 14, 2025 | filing ↗ | |
| Anup Arora | 6.9% | 13G | Feb 14, 2025 | filing ↗ | |
| Biotechnology Value Fund L P | 5.4% | 13G | May 15, 2026 | filing ↗ | |
| BVF I GP LLC | 5.4% | 13G | May 15, 2026 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Reg FD disclosure (7.01) | Jun 22, 2026 | filing ↗ |
| Other events (8.01) | Jun 22, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 22, 2026 | filing ↗ |
| Charter/bylaw changes (5.03) | May 20, 2026 | filing ↗ |
| Shareholder vote (5.07) | May 20, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 20, 2026 | filing ↗ |
| Earnings (2.02) | May 6, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 6, 2026 | filing ↗ |
| Officer/director changes (5.02) | Mar 31, 2026 | filing ↗ |
| Earnings (2.02) | Mar 4, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 4, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 12, 2026 | filing ↗ |
| Officer/director changes (5.02) | Nov 25, 2025 | filing ↗ |
| Earnings (2.02) | Nov 12, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 12, 2025 | filing ↗ |
| Exit or disposal costs (2.05) | Nov 3, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Nov 3, 2025 | filing ↗ |
| Other events (8.01) | Nov 3, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 3, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Sep 9, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 9, 2025 | filing ↗ |
| Officer/director changes (5.02) | Aug 14, 2025 | filing ↗ |
| Earnings (2.02) | Aug 12, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 12, 2025 | filing ↗ |